US Medical Device Reimbursement: Coverage, Coding, Payment and the RAPID Pathway

FDA clearance lets you sell a device. It does not mean anyone will pay for it. In the US, getting paid depends on three linked questions: will payers cover it, is there a code to bill it and what is the payment? This guide explains how the three work, the main Medicare programmes for new technology and the new RAPID coverage pathway, which was still a proposal when this was written in November 2026.

The three pillars

1. Coverage: whether a payer considers the item reasonable and necessary. Medicare coverage can be set nationally through a National Coverage Determination (NCD) or locally by Medicare Administrative Contractors (MACs) through Local Coverage Determinations (LCDs) or case-by-case decisions. Commercial payers set their own policies.
2. Coding: the codes used on claims, such as CPT codes for procedures and services, HCPCS Level II codes for supplies and many devices, and ICD-10 codes for diagnoses and inpatient procedures.
3. Payment: how much and how. Payment depends on the setting: hospital inpatient (IPPS, MS-DRGs), hospital outpatient (OPPS, APCs), physician fee schedule, ambulatory surgery centres and durable medical equipment fee schedules.

Hospitals care about all three because they buy the device and then bill for the procedure. A strong clinical story that lacks a reimbursement story often stalls in value analysis committees.

Evidence payers want

Regulatory evidence shows safety and effectiveness. Payers also ask whether the device improves health outcomes for their population, compared with existing options, and whether the results hold in Medicare-age patients. This is why many sponsors design clinical studies with payers in mind. See IDE and device clinical studies.

Medicare routes for new technology

• NTAP (New Technology Add-on Payment) adds payment for certain new technologies in inpatient care. CMS also has outpatient device pass-through payments. In the FY 2027 IPPS final rule, CMS repealed the alternative pathway for Breakthrough Devices for both NTAP and outpatient pass-through, starting with FY 2028 applications. Check current rules for your application year.
• TCET (Transitional Coverage for Emerging Technologies), finalised in 2024, was designed for certain Breakthrough Devices. CMS has paused it for new candidates while it implements RAPID.
• Parallel Review lets FDA and CMS review certain non-breakthrough devices at the same time. It remains available.

The RAPID coverage pathway

CMS and FDA announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway on April 23, 2026. CMS issued the proposed procedural notice on August 7, 2026, with comments due October 13, 2026. CMS said it would respond in a final notice, and the pathway is expected to take effect when that notice is published. When this article was written, check CMS for whether the final notice has been issued.

• Who it is for: Class III Breakthrough Devices, and certain Class II Breakthrough Devices that take part in FDA’s Total Product Life Cycle Advisory Program (TAP).
• Goal: to line up FDA authorisation with CMS national coverage so that coverage decisions follow quickly, within months rather than years.
• Not covered by the proposal: coding and payment for devices in the pathway, in vitro diagnostics (which are covered through MACs) and, in the proposal, devices still under investigation in an IDE pivotal study. Commenters have also questioned how many devices will actually qualify.

Treat RAPID as a pathway to watch rather than a plan to rely on until the final notice is out.

Practical steps for manufacturers

1. Start reimbursement planning during development, not after clearance.
2. Find existing codes that may apply, and whether a new code or a code change is needed.
3. Map the care setting and the payment system that applies.
4. Collect economic and outcomes evidence that fits payer questions.
5. Prepare materials for hospital value analysis committees and billing teams.
6. Keep promotional statements about coverage and payment accurate. Reimbursement support must follow the compliance rules in medical device sales compliance.

Why sales and clinical teams should care

Reps are often asked by hospitals “how is this paid?” before the first case. Knowing the basics of coding and payment helps you ask the right questions, set accurate expectations and escalate to your reimbursement team. If you are moving from pharma, this is one of the biggest new topics. See pharma sales vs medical device sales.

Frequently asked questions

Does FDA clearance guarantee Medicare coverage?

No. FDA decides whether a device can be marketed. Coverage, coding and payment are separate decisions made by CMS, MACs and other payers.

What is the difference between an NCD and an LCD?

An NCD applies nationally to Medicare. An LCD is issued by a MAC and applies in its region.

Is RAPID available now?

It was proposed in August 2026, and CMS said it would take effect with the final notice. Check CMS for the current status.

Do commercial payers follow Medicare?

Often they look to Medicare, but they set their own coverage policies and may require additional evidence.

Talk to the AptSkill team

Need help planning training on market access, regulatory strategy and clinical evidence? Send us a message.